Sandoz and Pear Therapeutics announced the launch of reSET-O, a new digital therapeutic for patients aged ≥18 years with opioid use disorder (OUD) currently under clinician care.
reSET-O was approved by the Food and Drug Administration (FDA) in December 2018. It is a 12-week (84-day) cognitive behavioral therapy application for use as adjunct to outpatient treatment; this consists of transmucosal buprenorphine and contingency management that offers incentives to reinforce positive behaviors. reSET-O is intended for use to increase retention of patients with OUD.
The patient can download and install reSET-O on their smartphone or tablet and enter an access code. Then the patient can complete lessons, answer quiz questions, report medication usage, substance use, cravings, and triggers. The Clinician Dashboard allows healthcare providers to track patients’ progress toward recovery, including their adherence to buprenorphine.
reSET-O is available by prescription only. reSET, indicated for substance use disorders that are not primarily opioid or alcohol, launched in November 2018.
“We believe prescription digital therapeutics can transform the way clinicians treat addiction by providing a way for patients to access treatment when and where it’s needed. reSET-O has been clinically proven to increase the likelihood that a patient will remain in treatment, while also providing a way for patients to access treatment anytime, anywhere, under clinician supervision,” stated Corey McCann, MD, PhD, President and CEO of Pear Therapeutics.
For more information call (833) 697-3738 or visit ResetforRecovery.com.
This article originally appeared on MPR